Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ponatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 0.99 |
| ▸ | BCR known ✓ | P11274 | 1/20 | 0.99 |
| ▸ | ABL2 | P42684 | 2/20 | 0.99 |
| ▸ | GAK | O14976 | 1/20 | 0.99 |
| ▸ | MLNR | O43193 | 1/20 | 0.99 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.99 |
| ▸ | JAK2 | O60674 | 1/20 | 0.99 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.99 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.99 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.99 |
| ▸ | EGFR | P00533 | 1/20 | 0.99 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.99 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.99 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.99 |
| ▸ | LCK | P06239 | 1/20 | 0.99 |
| ▸ | FYN | P06241 | 1/20 | 0.99 |
| ▸ | PGR | P06401 | 1/20 | 0.99 |
| ▸ | CSF1R | P07333 | 1/20 | 0.99 |
| ▸ | YES1 | P07947 | 1/20 | 0.99 |
| ▸ | LYN | P07948 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ponatinib SCHEMBL15798559 | 1.00 | ABL1 (0.99) | ABL1ABL2GAKMLNRRIPK2 | |
| Ponatinib SCHEMBL29495098 | 1.00 | ABL1 (0.99) | ABL1ABL2GAKMLNRRIPK2 | |
| Ponatinib SCHEMBL29528953 | 1.00 | ABL1 (0.99) | ABL1ABL2GAKMLNRRIPK2 | |
| Ponatinib SCHEMBL29889039 | 0.99 | ABL1 (1.00) | ABL1ABL2GAKMLNRRIPK2 | |
| Ponatinib SCHEMBL29353054 | 0.99 | ABL1 (1.00) | ABL1ABL2GAKMLNRRIPK2 | |
| Ponatinib SCHEMBL29373892 | 0.99 | ABL1 (1.00) | ABL1ABL2GAKMLNRRIPK2 | |
| Ponatinib SCHEMBL589260 | 0.99 | ABL1 (1.00) | ABL1ABL2GAKMLNRRIPK2 | |
| Ponatinib SCHEMBL16797824 | 0.99 | ABL1 (0.99) | ABL1ABL2GAKMLNRRIPK2 | |
| SCHEMBL591027 | 0.97 | ABL1 (1.00) | ABL1ABL2GAKMLNRRIPK2 | |
| Ponatinib SCHEMBL18304603 | 0.96 | ABL1 (0.94) | ABL1ABL2GAKMLNRRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2324 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| US-20260102373-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2026-04-16 | — | — | US | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| US-20260000769-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2026-01-01 | — | — | US | claimed |
| US-20250368655-A1 | SMALL MOLECULE INHIBITORS OF BCR-ABL | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2025-12-04 | — | — | US | claimed |
| US-12478683-B2 | Brush prodrugs and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-11-25 | — | — | US | claimed |
| US-20250352510-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2025-11-20 | — | — | US | claimed |
| US-20250325671-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2025-10-23 | — | — | US | claimed |
| EP-4630456-A1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND THERAPEUTIC USES THEREOF | Mythic Therapeutics, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| US-11384086-B2 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | ARIAD PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | claimed |
| US-20220211664-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2022-07-07 | — | — | US | claimed |
| WO-2022090953-A1 | A SOLID DISPERSION OF PONATINIB HYDROCHLORIDE AND PROCESS OF PREPARATION THEREOF | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2022-05-05 | — | — | WO | claimed |
| US-11311512-B2 | Lymph directing prodrugs | MONASH UNIVERSITY (AU) | 2022-04-26 | — | — | US | claimed |
| WO-2022036024-A9 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| US-20220096518-A1 | COMPOSITIONS AND METHODS FOR CANCER THERAPY | AIM IMMUNOTECH INC. (US) | 2022-03-31 | — | — | US | claimed |
| EP-3972982-A1 | BORONIC ESTER PRODRUGS AND USES THEREOF | Massachusetts Institute of Technology (US) | 2022-03-30 | — | — | EP | claimed |
| US-11279705-B2 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | ARIAD PHARMACEUTICALS, INC. (US) | 2022-03-22 | — | — | US | claimed |
| WO-2022036024-A2 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-02-17 | — | — | WO | claimed |
| US-20220028512-A1 | SMART DOSING FOR CANCER THERAPY | OptimDosing, LLC | 2022-01-27 | — | — | US | claimed |